| Literature DB >> 24504047 |
James E Siegler1, Muhammad Alvi2, Amelia K Boehme3, Michael J Lyerly2, Karen C Albright4, Reza Bavarsad Shahripour2, Pawan V Rawal2, Niren Kapoor2, April Sisson2, J Thomas Houston2, Anne W Alexandrov5, Sheryl Martin-Schild1, Andrei V Alexandrov2.
Abstract
BACKGROUND: Symptomatic intracerebral hemorrhage (sICH) remains the most feared complication of intravenous tissue plasminogen activator (IV tPA) treatment. We aimed to investigate how previously validated scoring methodologies would perform in treated patients in two US Stroke Belt states. METHODS ANDEntities:
Year: 2013 PMID: 24504047 PMCID: PMC3912845 DOI: 10.1155/2013/681673
Source DB: PubMed Journal: ISRN Stroke ISSN: 2090-9454
Risk scoring methodologies for hemorrhagic transformation or symptomatic intracerebral hemorrhage following thrombolytic therapy.
| Investigator | Score title | Primary | Points awarded | Conclusions |
|---|---|---|---|---|
| Cucchiara et al. [ | None | HT | 4-point score with 1 point allotted for
age >60 baseline NIHSS >10 baseline serum glucose >8.325mmol/L (150mg/dL) baseline platelet count <150,000/mm3 | Proportion of patients with HT
0 points: 2.6% 1 point: 9.7% 2 points: 15.1% 3 or 4 points: 37.9% (AUC 0.69) |
| Mazya et al. [ | SITS-sICH risk score | sICH | 12-point score with 1 point allotted for
baseline NIHSS 7–12 baseline systolic blood pressure ≥146mmHg age ≥72 years body weight ≥95 kg stroke onset to treatment time ≥180 min history of hypertension baseline NIHSS >12 baseline serum glucose ≥180mg/dL current use of aspirin (3 points if current use of combined aspirin and clopidogrel) | Proportion of patients with sICH
0 points: 0.2% ≥10 points: 14.3% (AUC 0.70) |
| Saposnik et al. [ | SPAN-100 | HT | Composite score considered positive if
age + baseline NIHSS ≥100 | Proportion of patients with HT
SPAN-100 positive group 42% SPAN-100 negative group 12% ( |
Table is not comprehensive.
HT denotes hemorrhagic transformation; NIHSS: National Institutes of Health Stroke Scale; sICH: symptomatic intracerebral hemorrhage; CT: computed tomography of the head; MCA: middle cerebral artery; SITS: safe implementation of treatments in stroke; SPAN: stroke prognostication using age and National Institutes of Health Stroke Scale score.
Comparision of patients who experienced sICH to those without sICH.
| No sICH | sICH | ||
|---|---|---|---|
| Age, median y (range) | 66 (20–99) | 68 (40–89) | 0.3117 |
| Race, no. Black (%) | 100 (22.8%) | 5 (26.3%) | 0.2538 |
| Gender, no. female (%) | 197 (45.5%) | 12 (63.2%) | 0.1307 |
| Arrived within 3 hours, no. (%) | 267 (63.1%) | 10 (58.8%) | 0.7191 |
| Intra-arterial thrombolysis, no. (%) | 15 (3.4%) | 2 (10.5%) | 0.3260 |
| Past medical history, no. (%) | |||
| Hyperlipidemia | 148 (34.0%) | 7 (36.8%) | 0.7994 |
| Hypertension | 319 (73.2%) | 15 (78.9%) | 0.5766 |
| Congestive heart failure | 49 (11.2%) | 1 (5.3%) | 0.257 |
| Atrial Fibrillation | 66 (15.2%) | 3 (15.8%) | 0.5722 |
| Diabetes | 117 (26.8%) | 6 (31.6%) | 0.6441 |
| Active smoker | 118 (27.1%) | 1 (5.9%) | 0.0317 |
| Laboratory values | |||
| Admission glucose, median mg/dL (range) | 115 (65–663) | 153 (78–536) | 0.0009 |
| Admission platelet <150.000 (%) | 6 (1.7%) | 0 (0.0%) | 0.7727 |
| INR, median (range) | 1.1 (0.7–2.3) | 1.1 (0.8–2.5) | 0.5794 |
| Home medications | |||
| Aspirin | 136 (56.2%) | 5 (38.5%) | 0.1049 |
| Clopidogrel | 65 (26.9%) | 3 (23.1%) | 0.2492 |
| Aspirin + clopidogrel | 33 (15.7%) | 2 (16.7%) | 0.3036 |
| Antihypertensive | 220 (50.2%) | 8 (44.4%) | 0.6305 |
| Oral diabetic medication | 68 (15.6%) | 1 (5.6%) | 0.1631 |
| Physical exam | |||
| Admission systolic blood pressure, median mmHg (range) | 157 (82–265) | 169 (100–260) | 0.3035 |
| Admission diastolic blood pressure, median mmHg (range) | 87 (45–187) | 91 (44–126) | 0.8446 |
| Admission NIHSS, median (range) | 9 (0–32) | 10 (0–20) | 0.5245 |
sICH denotes symptomatic intracranial hemorrhage; INR: international normalized ratio; and NIHSS: National Institutes of Health Stroke Scale score.
Figure 1Receiver operator characteristic assessing ability of scores to predict sICH for all patients (a), Black patients (b), and White patients (c). sICH denotes symptomatic intracranial hemorrhage, AUC area under the curve, SPAN-100 stroke prognostication using age and National Institutes of Health Stroke Scale score, and SITS safe implementation of treatments in stroke.
Odds of sICH according to selected scoring methodologies in our cohort of Stroke Belt patients.
| OR | Odds of sICH | ||
|---|---|---|---|
| Entire population | |||
| Cucchiara score | |||
| 4 groups (1, 2, 3, 4) | 2.02 | 1.08–3.81 | 0.0287 |
| 2 groups (>=3) | 3.42 | 0.90–12.9 | 0.0706 |
| SITS-sICH | |||
| 4 groups (0–2, 3–5, 6–8, 9–12) | 1.51 | 0.63–3.63 | 0.3593 |
| 2 groups (>=6) | 1.26 | 0.33–4.85 | 0.7364 |
| SPAN-100 | n/a | n/a | n/a |
| Black patients | |||
| Cucchiara score | |||
| 4 groups (1, 2, 3, 4) | 2.91 | 1.10–7.72 | 0.0318 |
| 2 groups (>=3) | 6.03 | 1.07–34.1 | 0.0422 |
| SITS-sICH | |||
| 4 groups (0–2, 3–5, 6–8, 9–12) | 1.64 | 0.54–4.97 | 0.3792 |
| 2 groups (>=6) | 1.24 | 0.24–6.38 | 0.8009 |
| SPAN-100 | n/a | n/a | n/a |
| White patients | |||
| Cucchiara score | |||
| 4 groups (1, 2, 3, 4) | 1.02 | 0.34–3.02 | 0.9730 |
| 2 groups (>=3) | n/a | n/a | n/a |
| SITS-sICH | |||
| 4 groups (0–2, 3–5, 6–8, 9–12) | 1.63 | 0.39–6.86 | 0.5049 |
| 2 groups (>=6) | 1.78 | 0.14–21.92 | 0.6535 |
| SPAN-100 | n/a | n/a | n/a |
SPAN-100 model was unable to converge in the present population.
sICH denotes symptomatic intracranial hemorrhage; OR: odds ratio; CI: confidence interval; SITS: safe implementation of treatments in stroke; SPAN-100: stroke prognostication using age and National Institutes of Health Stroke Scale score.
Figure 2Odds of sICH according to selected scoring methodologies in our cohort of Stroke Belt patients using (a) 4-group and (b) dichotomized comparisons. sICH denotes symptomatic intracranial hemorrhage and SITS safe implementation of treatments in stroke.
Figure 3Percentage of patients with sICH according to clinical score. Values represent percentage of patients who experienced sICH according to score type and score value. In the SITS-sICH score, low corresponds to 0–2 points, average corresponds to 3–5 points, moderate corresponds to 6–8 points, and high corresponds to 9–12 points. sICH denotes symptomatic intracranial hemorrhage, SITS safe implementation of treatments in stroke, and SPAN-100 stroke prognostication using age and National Institutes of Health Stroke Scale score.